E. A. Partridge

Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man

D. McKillop, Michael G. Hutchison, E. A. Partridge et al. · Xenobiotica · 2004 · 130 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

Effects of an allatostatin and a myosuppressin on midgut carbohydrate enzyme activity in the cockroach Diploptera punctata

Megumi Fusé, J.R Zhang, E. A. Partridge et al. · Peptides · 1999 · 127 citations

Life Sciences, Animal Sciences, Entomology +12

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

David McKillop, E. A. Partridge, John Kemp et al. · Molecular Cancer Therapeutics · 2005 · 125 citations

Medicine, Oncology, Pharmacology +16

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects

Paul Martín, Stuart Oliver, Sarah-Jane Kennedy et al. · Clinical Therapeutics · 2011 · 84 citations

Pharmacy, Pharmacokinetics, Pharmacology +6

A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil™ (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat

Eva M. Lenz, Ian D. Wilson, Brian Wright et al. · Journal of Pharmaceutical and Biomedical Analysis · 2002 · 48 citations

Pharmacy, Pharmacokinetics, Pharmacology +11